0001209191-14-009875.txt : 20140212
0001209191-14-009875.hdr.sgml : 20140212
20140212182658
ACCESSION NUMBER: 0001209191-14-009875
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140212
FILED AS OF DATE: 20140212
DATE AS OF CHANGE: 20140212
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001105533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562110007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
BUSINESS PHONE: 9192876300
MAIL ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
FORMER COMPANY:
FORMER CONFORMED NAME: MERIX BIOSCIENCE INC
DATE OF NAME CHANGE: 20000207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MIESOWICZ FREDERICK
CENTRAL INDEX KEY: 0001022855
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35443
FILM NUMBER: 14602021
MAIL ADDRESS:
STREET 1: CELLCOR INC
STREET 2: 200 WELLS AVE
CITY: NEWTON
STATE: MA
ZIP: 02159
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-02-12
0
0001105533
ARGOS THERAPEUTICS INC
ARGS
0001022855
MIESOWICZ FREDERICK
C/O ARGOS THERAPEUTICS, INC.
4233 TECHNOLOGY DRIVE
DURHAM
NC
27704
0
1
0
0
COO
Common Stock
2014-02-12
4
C
0
37
A
37
D
Common Stock
2014-02-12
4
C
0
619
A
656
D
Common Stock
2014-02-12
4
C
0
4941
A
5597
D
Series C Preferred Stock
2014-02-12
4
C
0
37
0.00
D
Common Stock
37
0
D
Series D Preferred Stock
2014-02-12
4
C
0
619
0.00
D
Common Stock
619
0
D
Series E Preferred Stock
2014-02-12
4
C
0
4941
0.00
D
Common Stock
4941
0
D
Each share of Series C Preferred Stock converted into 0.0074 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series C Preferred Stock has no expiration date.
Each share of Series D Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series D Preferred Stock has no expiration date.
Each share of Series E Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series E Preferred Stock has no expiration date.
/s/Frederick M. Miesowicz
2014-02-12